IL-10 Levels and Remote Ischemic Preconditioning in Acute Myocardial Infarction

Acute Myocardial Infarction Clinical Trial

Official title:

Interleukin-10 Levels and Remote Ischemic Preconditioning in Acute Myocardial Infarction.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01532206
• Other study ID #: NA_00069912
• Status: Terminated
• Phase: N/A
• First received: February 9, 2012
• Last updated: March 24, 2016
• Start date: March 2013
• Est. completion date: May 2014

Study information

• Verified date: March 2013
• Source: Johns Hopkins University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Remote ischemic preconditioning has proven beneficial in patients undergoing percutaneous coronary intervention and coronary artery bypass surgery. Animal studies suggest remote ischemic preconditioning increases levels of interleukin 10. The investigators aim to determine whether remote ischemic preconditioning results in an increase in IL-10 levels in patients following acute myocardial infarction.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: May 2014
• Est. primary completion date: February 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Acute myocardial infarction

Exclusion Criteria:

• Cardiogenic shock Active ischemia

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acute Myocardial Infarction
• Infarction
• Myocardial Infarction

Intervention

Other:
• Blood pressure cuff insufflation
Blood pressure cuff will be inflated to a pressure of 200mmHg for 5 minutes. This will be repeated x 3, separated by 5 minutes.

Locations

Country	Name	City	State
United States	Johns Hopkins Hospital	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Johns Hopkins University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Interleukin 10 levels		24 hours following RIPC	No